Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives von Shah, Rashmi R., Morganroth, Joel, Shah, Devron R.

Volltext

Moxifloxacin‐induced QTc interval prolongations in healthy male Japanese and Caucasian volunteers: a direct comparison in a thorough QT study von Morganroth, Joel, Wang, Yaning, Thorn, Michael, Kumagai, Yuji, Harris, Stuart, Stockbridge, Norman, Kleiman, Robert, Shah, Rashmi

Volltext

Telavancin versus Standard Therapy for Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: FAST 2 Study von STRYJEWSKI, Martin E, CHU, Vivian H, KITT, Michael M, COREY, G. Ralph, O'RIORDAN, William D, WARREN, Brian L, DUNBAR, Lala M, YOUNG, David M, VALLEE, Marc, FOWLER, Vance G, MORGANROTH, Joel, BARRIERE, Steven L

Volltext

A Randomized Trial Comparing the Cardiac Rhythm Safety of Moxifloxacin vs Levofloxacin in Elderly Patients Hospitalized With Community-Acquired Pneumonia von Morganroth, Joel, DiMarco, John P., Anzueto, Antonio, Niederman, Michael S., Choudhri, Shurjeel

Volltext

Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit von Shah, Rashmi R., Morganroth, Joel

Volltext

Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval) von Shah, Rashmi R., Morganroth, Joel, Shah, Devron R.

Volltext

Dealing with Global Safety Issues: Was the Response to QT-Liability of Non-Cardiac Drugs Well Coordinated? von Stockbridge, Norman, Morganroth, Joel, Shah, Rashmi R., Garnett, Christine

Volltext

Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy von Shah, Devron R., Shah, Rashmi R., Morganroth, Joel

Volltext

QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial von Dooley, Kelly E, Rosenkranz, Susan L, Conradie, Francesca, Moran, Laura, Hafner, Richard, von Groote-Bidlingmaier, Florian, Lama, Javier R., Shenje, Justin, De Los Rios, Jorge, Comins, Kyla, Morganroth, Joel, Diacon, Andreas H, Cramer, Yoninah S, Donahue, Kathleen, Maartens, Gary, Alli, Oladapo, Gottesman, Joan, Guevara, Maria, Hikuam, Chris, Hovind, Laura, Karlsson, Mats, McClaren, Jennifer, McIlleron, Helen, Murtaugh, William, Rolls, Barbara, Shahkolahi, Akbar, Stone, Lynnett, Tegha, Gerald, Tenai, Jacob, Upton, Caryn, Wimbish, Chanelle

Volltext

Relations of QTc prolongation on the electrocardiogram to torsades de pointes : definitions and mechanisms von MORGANROTH, J

Volltext

Electrocardiographic Effects of Rivastigmine von Morganroth, Joel, Graham, Stephen, Hartman, Richard, Anand, Ravi

Volltext

Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens von Tanneau, Lénaïg, Karlsson, Mats O., Rosenkranz, Susan L., Cramer, Yoninah S., Shenje, Justin, Upton, Caryn M., Morganroth, Joel, Diacon, Andreas H., Maartens, Gary, Dooley, Kelly E., Svensson, Elin M.

Volltext

ICH E 14 Q & A ( R 1) document: perspectives on the updated recommendations on thorough QT studies von Shah, Rashmi R., Morganroth, Joel

Volltext

Early Investigation of QTc Liability: The Role of Multiple Ascending Dose (MAD) Study von Shah, Rashmi R., Morganroth, Joel

Volltext

Early Investigation of QTc Liability von Shah, Rashmi R, Morganroth, Joel

Volltext

QT EFFECTS OF BEDAQUILINE, DELAMANID OR BOTH IN PATIENTS WITH RIFAMPICIN-RESISTANT-TB: A RANDOMIZED CONTROLLED TRIAL von Dooley, Kelly E., Rosenkranz, Susan L., Conradie, Francesca, Moran, Laura, Hafner, Richard, von Groote-Bidlingmaier, Florian, Lama, Javier R., Shenje, Justin, De Los Rios, Jorge, Comins, Kyla, Morganroth, Joel, Diacon, Andreas, Cramer, Yoninah S., Donahue, Kathleen, Maartens, Gary

Volltext

ICH E14 Q & A (R1) document: perspectives on the updated recommendations on thorough QT studies von Shah, Rashmi R., Morganroth, Joel

Volltext

Risk factors for the development of proarrhythmic events von Morganroth, Joel

Volltext

ICH E14 Q&A(R2) document: commentary on the further updated recommendations on thorough QT studies von Shah, Rashmi R., Morganroth, Joel, Kleiman, Robert B.

Volltext

Effect of single doses of IV palonosetron, up to 2.25 mg, on the QTc interval duration: a double-blind, randomized, parallel group study in healthy volunteers von Morganroth, Joel, Flaharty, Kristen K., Parisi, Simona, Moresino, Cecilia

Volltext